Drug Trial Radar · NCT02274623
Effect of CTAP101 Capsules on Ca/iPTH in Advanced Breast/Prostate Cancer Patients Treated With Denosumab/Zoledronic Acid
Last checked: Nov 19, 2026Latest source record: Sep 27, 2019 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
33
Actual
Start
Dec 2014
Primary completion
Feb 27, 2017
Study completion Mar 17, 2017
Sponsor
- Lead sponsor
- OPKO Health, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 24, 2014
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Supportive care
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label exploratory study of CTAP101 Capsules in patients with bone metastases arising from either breast or prostate cancer, who are taking anti-resorptive therapy.
Conditions
- Breast Cancer
- Prostate Cancer
- Bone Neoplasms
- Hypocalcemia
- Hyperparathyroidism, Secondary
Interventions
CTAP101 CapsulesDrug
escalating doses
Primary outcomes
What the sponsor says the trial is designed to measure.
- Effect of repeated, escalating doses of CTAP101 on serum calcium and plasma iPTH levelsTime frame: up to 52 weeks
- Effect of repeated, escalating daily doses of CTAP101 on serum calcifediolTime frame: up to 52 weeks
- Safety and tolerability of CTAP101Time frame: up to 52 weeks
Locations
6 sites in 1 country. Site status is shown where the registry gives one.
Coast Hematology-Oncology Associates
Long Beach, California
Mount Sinai Medical Center, Comprehensive Cancer Center
Miami, Florida
Research by Design LLC
Evergreen Park, Illinois
Roswell Park Cancer Institute
Buffalo, New York
University of Cincinnati Cancer Institute
Cincinnati, Ohio
Inova Dwight and Martha Schar Cancer Center
Fairfax, Virginia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.